Efficacy of anidulafungin against biofilms of different Candida species in long-term trials of continuous flow cultivation

Mycoses

Volumn 54, Issue 6, 2011, Pages

  Bernhardt, Hannelore ^a   Knoke, Manfred ^a   Bernhardt, Jörn ^b  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b Centre of Diagnostic and Interventional Endoscopy   (Germany)

Author keywords

Anidulafungin; Biofilm; Candida spp.; Long term continuous flow culture; Susceptibility

Indexed keywords

ANIDULAFUNGIN; VORICONAZOLE;

ARTICLE; BIOFILM; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CLAVISPORA LUSITANIAE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SENSITIVITY; FLOW RATE; IN VIVO STUDY; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; SPECIES DIFFERENTIATION;

AEROBIOSIS; ANAEROBIOSIS; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; CANDIDEMIA; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS;

EID: 80054006415     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02036.x     Document Type: Article

References (23)

1. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture and drug resistance. J Bacteriol 2001; 183: 5385-94.
2. D'Enfert C. Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr Drug Targets 2006; 7: 465-70.
3. Chandra J, Zhou G, Ghannoum MA. Fungal biofilms and antimycotics. Curr Drug Targets 2005; 6: 887-94.
4. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
5. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82.
6. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27.
7. Samaranayake YH, Ye J, Yau YY, Cheung BPK, Samaranayake LP. In vitro method to study antifungal perfusion in Candida biofilms. J Clin Microbiol 2005; 43: 818-25.
8. Bernhardt H, Knoke M. Was bieten Candida-Biofilme Besonderes? Something special of Candida biofilms? Mycoses 2008; 51(Suppl. 3): 33-38.
9. Mukherjee PK, Zhou G, Munyon R, Ghannoum MA. Candida biofilm: a well-designed protected environment. Med Mycol 2005; 43: 191-208.
10. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44: 590-8.
11. Cohen-Wolkowiez M, Benjamin DK Jr, Steinbach WJ, Smith PB. Anidulafungin: a new echinocandin for the treatment of fungal infections. Drugs Today 2006; 42: 533-44.
12. Seneviratne CJ, Samaranayake YH, Samaranayake LP. Cell density and cell ageing as factors modulating antifungal resistance of Candida albicans biofilms. Antimicrob Agents Chemother 2008; 52: 3259-66.
13. Khot PD, Suci PA, Miller RL, Nelson RD, Tyler BJ. A small subpopulation of blastospores in Candida albicans biofilms exhibit resistance to amphotericin B associated with differential regulation of ergosterol and β-1, 6-glucan pathway genes. Antimicrob Agents Chemother 2006; 50: 3708-16.
14. Al-Fattani MA, Douglas LJ. Penetration of Candida biofilms by antifungal agents. Antimicrob Agents Chemother 2004; 48: 3291-7.
15. Baillie GS, Douglas LJ. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob Agents Chemother 1998; 42: 1900-5.
16. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
17. LaFleur MD, Kumamoto CA, Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 2006; 50: 3839-46.
18. Perumal P, Mekala S, Chaffin WL. Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob Agents Chemother 2007; 51: 2454-63.
19. Biswas SK, Chaffin WL. Anaerobic growth of Candida albicans does not support biofilm formation under similar conditions used for aerobic biofilm. Curr Microbiol 2005; 51: 100-4.
20. Jacobson MJ, Piper KE, Nguyen G, Steckelberg JM, Patel R. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother 2008; 52: 2242-3.
21. Katragkou A, Chatzimoschou A, Simitsopoulou M et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob Agents Chemother 2008; 52: 357-60.
22. Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D et al. Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother 2008; 52: 1506-9.
23. Melo AS, Colombo AL, Arthington-Skaggs BA. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob Agents Chemother 2007; 51: 3081-8.